Table 3.

Summary of findings table on the role of aromatase inhibitors in managing hypogonadism in adult males related to obesity and aging: A systematic review and meta-analysis

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)
	Risk with Control	Risk with Aromatase Inhibitors
Total testosterone (3 months)	The mean total testosterone (3 months) was 10.43 nmol/l	MD 7.08 nmol/l higher (5.92 higher to 8.24 higher)	-	118 (3 RCTs)	⨁⨁⨁⨁High
Estradiol (3 months)	The mean estradiol (3 months) was 93.73 pmol/l	MD 3.07 pmol/l lower (5.27 lower to 0.87 lower)	-	118 (3 RCTs)	⨁⨁⨁⨁High
Luteinizing hormone (3 months)	The mean luteinizing hormone (3 months) was 5.03 U/l	MD 1.79 U/l higher (0.77 higher to 2.81 higher)	-	118 (3 RCTs)	⨁⨁⨁⨁High
Severe adverse events (SAEs)	33 per 1,000	79 per 1,000 (14 to 336)	OR 2.48 (0.42 to 14.66)	118 (3 RCTs)	⨁⨁⨁⨁High
Treatment emergent adverse events (TAEs)	117 per 1,000	164 per 1,000 (58 to 381)	OR 1.48 (0.47 to 4.66)	118 (3 RCTs)	⨁⨁⨁⨁High

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI); CI: confidence interval; MD: mean difference; OR: odds ratio. GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect